Hongene Biotech Demonstrates Advanced siRNA Manufacturing Capabilities Through SiranBio's Dual-Target Hepatitis B Program
核心洞察
Hongene Biotech Corporation (搜索) has successfully supported SiranBio (搜索)'s SA1211 programme, a dual-target siRNA candidate for chronic hepatitis B (搜索), demonstrating advanced oligonucleotide CDMO capabilities.
The collaboration showcased Hongene's vertically integrated services spanning raw materials production, process development, analytical development, and current Good Manufacturing Practice manufacturing.
The programme highlights the increasing complexity of next-generation siRNA therapeutics and the critical importance of robust synthesis, impurity control, and scale-up capabilities.
Hongene Biotech Corporation (搜索) has announced its successful support of SiranBio (搜索)'s SA1211 programme, a dual-target siRNA candidate for chronic hepatitis B (搜索), demonstrating the company's advanced oligonucleotide contract development and manufacturing organization (CDMO) capabilities for structurally complex RNA therapeutics.
Comprehensive Manufacturing Support
Hongene provided vertically integrated CDMO services for the SA1211 programme, encompassing raw materials production, process development, analytical development, current Good Manufacturing Practice (cGMP) drug substance and drug product manufacturing, and regulatory and chemistry, manufacturing, and controls (CMC) support. This end-to-end approach addresses the growing complexity demands of next-generation siRNA therapeutics.
The programme underscores the critical importance of robust capabilities in synthesis, impurity control, scale-up, and clinical-stage manufacturing as siRNA designs become increasingly sophisticated.
Technology Platform Evolution
"Programmes like SA1211 show where the field is heading," said Dr. David Butler, chief technology officer at Hongene. "As siRNA designs become more complex, the bar for development and CMC execution rises with them. Our role is to give customers the technical depth and manufacturing flexibility to move these molecules forward with confidence."
While SA1211 was manufactured using traditional solid-phase oligonucleotide synthesis, Hongene is already applying its chemoenzymatic ligation platform to other complex dual-targeting siRNA programs in development. Dr. Butler noted that for next-generation constructs, the company expects ligation to provide "a highly attractive route to modular, high-purity, and scalable manufacturing."
Strategic Positioning in RNA Therapeutics
The SA1211 programme further reinforces Hongene's position as a specialized CDMO partner for innovative oligonucleotide therapeutics, particularly where molecular complexity and manufacturing execution are critical to program success. Founded in 1998 and incorporated in Singapore, Hongene brings nearly 30 years of RNA-focused expertise to support biotech and pharmaceutical partners worldwide.
The collaboration highlights the evolving landscape of RNA therapeutics, where dual-target approaches represent an advancement in therapeutic design complexity, requiring sophisticated manufacturing capabilities to ensure successful clinical development and commercialization.